D Nance1, R A Campbell2, J W Rowley2,3, J M Downie4, L B Jorde4, W H Kahr5,6,7, S A Mereby2, N D Tolley2, G A Zimmerman3, A S Weyrich2,3, M T Rondina2,3,8. 1. The Division of Hematology, University of Utah, Salt Lake City, UT, USA. 2. Molecular Medicine Program, University of Utah, Salt Lake City, UT, USA. 3. Department of Internal Medicine, University of Utah, Salt Lake City, UT, USA. 4. Department of Human Genetics, University of Utah, Salt Lake City, UT, USA. 5. Department of Paediatrics, Division of Haematology/Oncology, University of Toronto, Toronto, ON, Canada. 6. Program in Cell Biology, Research Institute, Hospital for Sick Children, University of Toronto, Toronto, ON, Canada. 7. Department of Biochemistry, University of Toronto, Toronto, ON, Canada. 8. GRECC, George E. Wahlen Salt Lake City VAMC, Salt Lake City, UT, USA.
Abstract
Essentials Co-existent damaging variants are likely to cause more severe bleeding and may go undiagnosed. We determined pathogenic variants in a three-generational pedigree with excessive bleeding. Bleeding occurred with concurrent variants in prostaglandin synthase-1 (PTGS-1) and factor VIII. The PTGS-1 variant was associated with functional defects in the arachidonic acid pathway. SUMMARY: Background Inherited human variants that concurrently cause disorders of primary hemostasis and coagulation are uncommon. Nevertheless, rare cases of co-existent damaging variants are likely to cause more severe bleeding and may go undiagnosed. Objective We prospectively sought to determine pathogenic variants in a three-generational pedigree with excessive bleeding. Patients/methods Platelet number, size and light transmission aggregometry to multiple agonists were evaluated in pedigree members. Transmission electron microscopy determined platelet morphology and granule content. Thromboxane release studies and light transmission aggregometry in the presence or absence of prostaglandin G2 assessed specific functional defects in the arachidonic acid pathway. Whole exome sequencing (WES) and targeted nucleotide sequence analysis identified potentially deleterious variants. Results Pedigree members with excessive bleeding had impaired platelet aggregation with arachidonic acid, epinephrine and low-dose ADP, as well as reduced platelet thromboxane B2 release. Impaired platelet aggregation in response to 2MesADP was rescued with prostaglandin G2 , a prostaglandin intermediate downstream of prostaglandin synthase-1 (PTGS-1) that aids in the production of thromboxane. WES identified a non-synonymous variant in the signal peptide of PTGS-1 (rs3842787; c.50C>T; p.Pro17Leu) that completely co-segregated with disease phenotype. A variant in the F8 gene causing hemophilia A (rs28935203; c.5096A>T; p.Y1699F) was also identified. Individuals with both variants had more severe bleeding manifestations than characteristic of mild hemophilia A alone. Conclusion We provide the first report of co-existing variants in both F8 and PTGS-1 genes in a three-generation pedigree. The PTGS-1 variant was associated with specific functional defects in the arachidonic acid pathway and more severe hemorrhage.
Essentials Co-existent damaging variants are likely to cause more severe bleeding and may go undiagnosed. We determined pathogenic variants in a three-generational pedigree with excessive bleeding. Bleeding occurred with concurrent variants in prostaglandin synthase-1 (PTGS-1) and factor VIII. The PTGS-1 variant was associated with functional defects in the arachidonic acid pathway. SUMMARY: Background Inherited human variants that concurrently cause disorders of primary hemostasis and coagulation are uncommon. Nevertheless, rare cases of co-existent damaging variants are likely to cause more severe bleeding and may go undiagnosed. Objective We prospectively sought to determine pathogenic variants in a three-generational pedigree with excessive bleeding. Patients/methods Platelet number, size and light transmission aggregometry to multiple agonists were evaluated in pedigree members. Transmission electron microscopy determined platelet morphology and granule content. Thromboxane release studies and light transmission aggregometry in the presence or absence of prostaglandin G2 assessed specific functional defects in the arachidonic acid pathway. Whole exome sequencing (WES) and targeted nucleotide sequence analysis identified potentially deleterious variants. Results Pedigree members with excessive bleeding had impaired platelet aggregation with arachidonic acid, epinephrine and low-dose ADP, as well as reduced platelet thromboxane B2 release. Impaired platelet aggregation in response to 2MesADP was rescued with prostaglandin G2 , a prostaglandin intermediate downstream of prostaglandin synthase-1 (PTGS-1) that aids in the production of thromboxane. WES identified a non-synonymous variant in the signal peptide of PTGS-1 (rs3842787; c.50C>T; p.Pro17Leu) that completely co-segregated with disease phenotype. A variant in the F8 gene causing hemophilia A (rs28935203; c.5096A>T; p.Y1699F) was also identified. Individuals with both variants had more severe bleeding manifestations than characteristic of mild hemophilia A alone. Conclusion We provide the first report of co-existing variants in both F8 and PTGS-1 genes in a three-generation pedigree. The PTGS-1 variant was associated with specific functional defects in the arachidonic acid pathway and more severe hemorrhage.
Authors: Geraldine A Van der Auwera; Mauricio O Carneiro; Christopher Hartl; Ryan Poplin; Guillermo Del Angel; Ami Levy-Moonshine; Tadeusz Jordan; Khalid Shakir; David Roazen; Joel Thibault; Eric Banks; Kiran V Garimella; David Altshuler; Stacey Gabriel; Mark A DePristo Journal: Curr Protoc Bioinformatics Date: 2013
Authors: M T Rondina; H Schwertz; E S Harris; B F Kraemer; R A Campbell; N Mackman; C K Grissom; A S Weyrich; G A Zimmerman Journal: J Thromb Haemost Date: 2011-04 Impact factor: 5.824
Authors: Craig R Lee; Frank G Bottone; Joseph M Krahn; Leping Li; Harvey W Mohrenweiser; Molly E Cook; Robert M Petrovich; Douglas A Bell; Thomas E Eling; Darryl C Zeldin Journal: Pharmacogenet Genomics Date: 2007-02 Impact factor: 2.089
Authors: M Higuchi; H H Kazazian; L Kasch; T C Warren; M J McGinniss; J A Phillips; C Kasper; R Janco; S E Antonarakis Journal: Proc Natl Acad Sci U S A Date: 1991-08-15 Impact factor: 11.205
Authors: Goncalo R Abecasis; Adam Auton; Lisa D Brooks; Mark A DePristo; Richard M Durbin; Robert E Handsaker; Hyun Min Kang; Gabor T Marth; Gil A McVean Journal: Nature Date: 2012-11-01 Impact factor: 49.962
Authors: Hashem A Shihab; Julian Gough; David N Cooper; Peter D Stenson; Gary L A Barker; Keith J Edwards; Ian N M Day; Tom R Gaunt Journal: Hum Mutat Date: 2012-11-02 Impact factor: 4.878
Authors: Melissa V Chan; Melissa A Hayman; Suthesh Sivapalaratnam; Marilena Crescente; Harriet E Allan; Matthew L Edin; Darryl C Zeldin; Ginger L Milne; Jonathan Stephens; Daniel Greene; Moghees Hanif; Valerie B O'Donnell; Liang Dong; Michael G Malkowski; Claire Lentaigne; Katherine Wedderburn; Matthew Stubbs; Kate Downes; Willem H Ouwehand; Ernest Turro; Nihr BioResource; Daniel P Hart; Kathleen Freson; Michael A Laffan; Timothy D Warner Journal: Haematologica Date: 2021-05-01 Impact factor: 9.941